Eventide Asset Management’s Loxo Oncology, Inc LOXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-274,000
| Closed | -$38.4M | – | 140 |
|
|
2018
Q4 | $38.4M | Buy |
274,000
+45,000
| +20% | +$6.83M | 1.7% | 16 |
|
|
2018
Q3 | $39.1M | Hold |
229,000
| – | – | 1.44% | 22 |
|
|
2018
Q2 | $39.7M | Hold |
229,000
| – | – | 1.65% | 17 |
|
|
2018
Q1 | $26.4M | Sell |
229,000
-56,000
| -20% | -$5.96M | 1.24% | 31 |
|
|
2017
Q4 | $24M | Hold |
285,000
| – | – | 1.25% | 32 |
|
|
2017
Q3 | $26.3M | Sell |
285,000
-245,000
| -46% | -$19M | 1.49% | 26 |
|
|
2017
Q2 | $42.5M | Sell |
530,000
-49,000
| -8% | -$2.72M | 2.65% | 6 |
|
|
2017
Q1 | $24.4M | Sell |
579,000
-161,000
| -22% | -$6.63M | 1.61% | 25 |
|
|
2016
Q4 | $23.8M | Hold |
740,000
| – | – | 1.55% | 26 |
|
|
2016
Q3 | $19.4M | Hold |
740,000
| – | – | 1.18% | 33 |
|
|
2016
Q2 | $17.2M | Hold |
740,000
| – | – | 1.05% | 36 |
|
|
2016
Q1 | $20.2M | Buy |
740,000
+186,700
| +34% | +$3.91M | 1.13% | 35 |
|
|
2015
Q4 | $15.7M | Buy |
553,300
+214,100
| +63% | +$5.75M | 0.79% | 48 |
|
|
2015
Q3 | $5.93M | Buy |
339,200
+95,500
| +39% | +$1.87M | 0.34% | 69 |
|
|
2015
Q2 | $4.39M | Buy |
243,700
+129,100
| +113% | +$1.76M | 0.24% | 81 |
|
|
2015
Q1 | $1.43M | Buy |
+114,600
| New | +$1.43M | 0.11% | 102 |
|
Other funds holding LOXO
Eventide Asset Management's LOXO Position: Q1 2019 in Review
Eventide Asset Management sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 274,000 shares — an estimated $38.4M sold.
Eventide Asset Management first reported a position in LOXO in Q1 2015 and held it in 16 quarters. The position peaked at $42.5M in Q2 2017. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.
- Eventide Asset Management reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
- Eventide Asset Management sold 274,000 Loxo Oncology, Inc shares in Q1 2019, an estimated $38.4M.
- Eventide Asset Management first reported a position in Loxo Oncology, Inc in Q1 2015 and held it in 16 quarters.
- Eventide Asset Management's Loxo Oncology, Inc position peaked at $42.5M in Q2 2017.
- 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.
Based on Eventide Asset Management's 13F filing for Q1 2019, filed 15 May 2019.